Latest Biospecifics Technologies Corp (BSTC) Headl
Post# of 14
Posted On: 03/12/2014 6:50:49 PM
Latest Biospecifics Technologies Corp (BSTC) Headlines
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Mar 06, 7:00AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2013 and provided a corporate update.
Auxilium Pharma Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 10:00AM CST
Revenues were boosted by the recently acquired subsidiary, Actient, as well as higher Xiaflex sales in the U.S.
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Monday
Alcobra (ADHD) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:04AM CST
Alcobra Ltd. was a big mover last session, as the company saw its shares rise by over 8% on the day.
Durata Therapeutics (DRTX) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:21AM CST
Durata Therapeutics, Inc. (DRTX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Friday
Positive Data on BioSpecifics/ Auxilium's Xiaflex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 11:10AM CST
BioSpecifics Technologies recently announced encouraging top-line data on Xiaflex from a phase II dose escalation clinical trial for the treatment of human lipoma.
Biotech Stock Roundup: Christmas Gift for UTHR, TSRO Tumbles - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jan 02, 9:48AM CST
Altogether it was a slow week for the biotech sector though companies like UTHR made the headlines.
Update on BioSpecifics/ Auxilium's Xiaflex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 27, 3:20PM CST
BioSpecifics Technologies is working hard to develop its pipeline .
Pipeline Progress at Auxilium Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 2:35PM CST
Auxilium Pharmaceuticals recently dosed its first patient for the phase II study on Xiaflex for the treatment of frozen shoulder syndrome (adhesive capsulitis).
Auxilium Up on Peyronie's Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 9:40AM CST
Xiaflex, currently marketed for Dupuytren's Contracture, gained FDA approval for Peyronie's disease.
Zacks #1 Rank Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Monday
BioSpecifics Technologies Corp. (BSTC) in Focus: Stock Moves 6.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 7:21AM CST
BioSpecifics Technologies Corp. (BSTC) was a big mover last session, as the company saw its shares rise by roughly 7% on the day.
FDA approves first drug for rare erection disorder
AP - Fri Dec 06, 1:34PM CST
WASHINGTON (AP) — The Food and Drug Administration on Friday approved the first drug to treat an unusual condition that causes painful, curved erections in men.
Cadence Pharmaceuticals Inc. (CADX) Jumps: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 04, 7:32AM CST
Cadence Pharmaceuticals Inc. was a big mover last session, as the company saw its shares rise over 6% on the day.
Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 03, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Tuesday
Data on Auxilium Pharma's Xiaflex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 22, 10:10AM CST
Auxilium Pharma announced encouraging results on Xiaflex from the MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren's) study.
Regulatory Setback for Forest/Gedeon - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 22, 9:30AM CST
Forest Labs and Gedeon Richter intend to meet with the FDA shortly to determine the path forward for cariprazine.
QLT (QLTI) Surges: Stock Moves 11.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 21, 6:37AM CST
QLT Inc. was a big mover last session, as the company saw its shares rise nearly 12% on the day.
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Mar 06, 7:00AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2013 and provided a corporate update.
Auxilium Pharma Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 10:00AM CST
Revenues were boosted by the recently acquired subsidiary, Actient, as well as higher Xiaflex sales in the U.S.
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Monday
Alcobra (ADHD) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:04AM CST
Alcobra Ltd. was a big mover last session, as the company saw its shares rise by over 8% on the day.
Durata Therapeutics (DRTX) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:21AM CST
Durata Therapeutics, Inc. (DRTX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Friday
Positive Data on BioSpecifics/ Auxilium's Xiaflex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 11:10AM CST
BioSpecifics Technologies recently announced encouraging top-line data on Xiaflex from a phase II dose escalation clinical trial for the treatment of human lipoma.
Biotech Stock Roundup: Christmas Gift for UTHR, TSRO Tumbles - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jan 02, 9:48AM CST
Altogether it was a slow week for the biotech sector though companies like UTHR made the headlines.
Update on BioSpecifics/ Auxilium's Xiaflex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 27, 3:20PM CST
BioSpecifics Technologies is working hard to develop its pipeline .
Pipeline Progress at Auxilium Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 2:35PM CST
Auxilium Pharmaceuticals recently dosed its first patient for the phase II study on Xiaflex for the treatment of frozen shoulder syndrome (adhesive capsulitis).
Auxilium Up on Peyronie's Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 9:40AM CST
Xiaflex, currently marketed for Dupuytren's Contracture, gained FDA approval for Peyronie's disease.
Zacks #1 Rank Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Monday
BioSpecifics Technologies Corp. (BSTC) in Focus: Stock Moves 6.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 7:21AM CST
BioSpecifics Technologies Corp. (BSTC) was a big mover last session, as the company saw its shares rise by roughly 7% on the day.
FDA approves first drug for rare erection disorder
AP - Fri Dec 06, 1:34PM CST
WASHINGTON (AP) — The Food and Drug Administration on Friday approved the first drug to treat an unusual condition that causes painful, curved erections in men.
Cadence Pharmaceuticals Inc. (CADX) Jumps: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 04, 7:32AM CST
Cadence Pharmaceuticals Inc. was a big mover last session, as the company saw its shares rise over 6% on the day.
Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 03, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Tuesday
Data on Auxilium Pharma's Xiaflex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 22, 10:10AM CST
Auxilium Pharma announced encouraging results on Xiaflex from the MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren's) study.
Regulatory Setback for Forest/Gedeon - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 22, 9:30AM CST
Forest Labs and Gedeon Richter intend to meet with the FDA shortly to determine the path forward for cariprazine.
QLT (QLTI) Surges: Stock Moves 11.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 21, 6:37AM CST
QLT Inc. was a big mover last session, as the company saw its shares rise nearly 12% on the day.
(0)
(0)